Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20349548 | 0.89 | HRH3 (0.50) | EPHX2CYP2D6HRH3NAAAGAA | |
| SCHEMBL18390139 | 0.81 | GAA (0.40) | EPHX2NAAAGAATSHRALDH1A1 | |
| SCHEMBL20965310 | 0.77 | GAA (0.38) | EPHX2NAAAGAATSHRALDH1A1 | |
| SCHEMBL20328130 | 0.77 | SMN1; SMN2 (0.46) | EPHX2NAAAGAATSHRALDH1A1 | |
| SCHEMBL20349560 | 0.76 | SMN1; SMN2 (0.43) | EPHX2CYP2D6HRH3GAATSHR | |
| SCHEMBL18713061 | 0.74 | HRH3 (0.47) | EPHX2CYP2D6HRH3GAATSHR | |
| SCHEMBL18390123 | 0.73 | POLB (0.58) | EPHX2TSHRALDH1A1LMNARET | |
| SCHEMBL20353490 | 0.73 | GAA (0.38) | EPHX2NAAAGAATSHRALDH1A1 | |
| SCHEMBL25595643 | 0.72 | HRH3 (0.43) | HRH3TSHRALDH1A1 | |
| SCHEMBL21016656 | 0.71 | HRH3 (0.34) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | EPHX2 2061/4885CYP2D6 3133/4885HRH3 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.